**Summary of Screen Results**

**Compound Target**
- SPM Score*
- **Sensitive**
  - Targeted Neratinib EGFR, HER1, HER2, and HER4.
  - Irreversible binding 91.6
- **Resistant Chemos**
  - Cyclophosphamide Alkylating agent 40.9
  - Doxorubicin Intercalating agent 30.5
  - Docetaxel Microtubule inhibitor 17.8
  - Tamoxifen Nonsteroidal antiestrogen 13.6
  - Gemcitabine Pyrimidine nucleoside analog 12.4
  - Paclitaxel Microtubules 9.7

---

**Live Tumor Sample Collected**

**Robotic Testing of Drugs and Drug Combinations**

**Oncologist Receives an Actionable Report Prioritizing Treatments**

---

**Discovering Effective, Less-Toxic Treatments for Each Patient’s Unique Cancer**

**How the PARIS® Test Works**

Every patient’s cancer is different and deserves personalized treatment. Despite the expansion of genetic profiling, few patients receive individualized cancer profiles that can lead to the selection of life-saving drugs. SEngine Precision Medicine’s proprietary PARIS® Test aids in identifying effective and less-toxic therapies available for patients with solid cancer tumors.

SEngine Precision Medicine integrates the most up-to-date robotics technology with decades of knowledge in cancer genetics and a deep understanding of the behavior of cancer cells. SEngine Precision Medicine combines data from ex-vivo testing of your tumor with genomics and clinical data to identify the best possible drug matches for your cancer. The PARIS® Test also rules out therapies which will most likely not help your specific case, saving time, money, and exposure to debilitating side effects.

**Discuss the PARIS® Test with your oncologist when:**

- Your cancer has recurred and the standard of care offers little hope
- You are trying to decide which clinical trial is right for you
- Your cancer is of unknown origin and the therapeutics path is not defined
- Your cancer is rare, has not been studied, or no effective treatments are available
- Your cancer has no treatment options

Contact us today to initiate screening or learn more.

SEngineMedicine.com
SEngine Precision Medicine's PARIS® Test aids in matching each patient with effective and less-toxic therapies.

**Requirements for the PARIS® Test:**

- At least four or more core biopsies or
- A surgical resection, at least 0.5 to 1 cm in diameter or
- Body fluids (pleural effusion or ascites >250 ml)

The larger the fresh sample, the more successful the isolation of live cells leading to faster results.

**Personalized Drug Screening**

Our lab tests your cancer with agents that have been compiled to target the widest range of cancer pathways. Our drug library contains more than 140 drugs including:

- FDA-approved chemotherapies
- FDA-approved, most advanced targeted therapies
- Drugs currently in clinical trials

**Fast Turnaround**

SEngine Precision Medicine provides a comprehensive report with prioritized drug choices and a SPM Score based on your cancer cell response and genomic data. Our two- to six-week turnaround provides critical data to guide treatment without delay.

Contact us today to initiate screening or learn more.

SEngineMedicine.com